Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/12/21	TearLab Corporation Announces Board Appointments	CI
09/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
28/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/07/20	TearLab Corporation to Seek Acquisitions	CI
26/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/05/20	TearLab Corporation Announces Board Appointments	CI
11/05/20	Tearlab Mulls Inorganic Growth Opportunities	CI
11/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/06/20	TearLab: 1Q Earnings Snapshot	AQ
26/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
Benjamin Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
09/07/20	Joseph Jensen	Tender	Chief Executive Officer	29,206	0.1196%
09/07/20	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%	-
09/07/20	Paul M. Karpecki	Tender	Director	102,200	0.4187%

TearLab Corporation Stock

Stocks

Medical Equipment, Supplies & Distribution

Latest news: TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ABBOTT LABORATORIES	-3.23%	+3.51%	-12.02%	+15.72%	190B
MEDTRONIC PLC	-2.90%	+5.45%	+13.04%	+38.65%	125B
STRYKER CORPORATION	-2.75%	+11.65%	-7.90%	+17.71%	124B
ESSILORLUXOTTICA	+0.96%	+5.15%	-38.02%	+12.24%	99.31B
CENCORA, INC.	-1.80%	+0.82%	-7.41%	+69.42%	63.65B
BECTON, DICKINSON AND COMPANY	-0.78%	+7.07%	+19.44%	-18.22%	57.71B
IDEXX LABORATORIES, INC.	+0.79%	+22.65%	-5.28%	+59.81%	53.26B
HOYA CORPORATION	-6.98%	-14.56%	-12.60%	+42.69%	47.03B
ALCON INC.	-2.36%	+3.72%	+3.27%	-8.07%	36.15B
Average	-1.90%	+5.27%	-5.28%	+25.55%	88.46B
Weighted average by Cap.	-2.20%	+5.71%	-6.94%	+24.48%